Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum

Core Insights - Cencora, Inc. is identified as a strong healthcare stock for 2026, with Morgan Stanley upgrading its rating from Equalweight to Overweight and raising the price target to $400 due to its robust position in specialty pharmaceuticals and the upcoming majority acquisition of OneOncology [1][2] Financial Performance and Growth Projections - Analysts have increased Cencora's FY2026 U.S. Healthcare Solutions AOI growth forecast to 10.8% and International AOI growth to 7.0%, leading to an EPS estimate of $17.63, which is slightly above consensus [2] - Following the announcement of credit agreements, Jefferies upgraded Cencora to a Buy from Hold and raised the price target from $330 to $440, citing the company's strong execution and enhanced long-term plans as key investment factors [5] Acquisition Financing - Cencora entered into credit agreements totaling $4.5 billion to finance the acquisition of OneOncology, which includes a $1.5 billion term credit agreement with JPMorgan Chase Bank and a separate $3 billion term loan facility with Citibank [3][4] - The proceeds from these credit agreements will be used for acquisition consideration, debt repayment, and covering related fees and expenses, with funding contingent on the successful completion of the acquisition [4]